Brajovic S - Search Results

1

Evaluation of Natural Language Processing (NLP) systems to annotate drug product labeling with MedDRA terminology.

Ly T, Pamer C, Dang O, Brajovic S, Haider S, Botsis T, Milward D, Winter A, Lu S, Ball R. Ly T, et al. Among authors: brajovic s. J Biomed Inform. 2018 Jul;83:73-86. doi: 10.1016/j.jbi.2018.05.019. Epub 2018 Jun 1. J Biomed Inform. 2018. PMID: 29860093 Free article.

2

ADE Eval: An Evaluation of Text Processing Systems for Adverse Event Extraction from Drug Labels for Pharmacovigilance.

Bayer S, Clark C, Dang O, Aberdeen J, Brajovic S, Swank K, Hirschman L, Ball R. Bayer S, et al. Among authors: brajovic s. Drug Saf. 2021 Jan;44(1):83-94. doi: 10.1007/s40264-020-00996-3. Epub 2020 Oct 2. Drug Saf. 2021. PMID: 33006728 Free PMC article.

3

Validating a Framework for Coding Patient-Reported Health Information to the Medical Dictionary for Regulatory Activities Terminology: An Evaluative Study.

Brajovic S, Blaser DA, Zisk M, Caligtan C, Okun S, Hall M, Pamer CA. Brajovic S, et al. JMIR Med Inform. 2018 Aug 21;6(3):e42. doi: 10.2196/medinform.9878. JMIR Med Inform. 2018. PMID: 30131314 Free PMC article.

4

Quality assessment of spontaneous triggered adverse event reports received by the Food and Drug Administration.

Brajovic S, Piazza-Hepp T, Swartz L, Dal Pan G. Brajovic S, et al. Pharmacoepidemiol Drug Saf. 2012 Jun;21(6):565-70; discussion 571-2. doi: 10.1002/pds.3223. Epub 2012 Feb 22. Pharmacoepidemiol Drug Saf. 2012. PMID: 22359404 Review.

5

Postmarket Safety Outcomes for New Molecular Entity (NME) Drugs Approved by the Food and Drug Administration Between 2002 and 2014.

Pinnow E, Amr S, Bentzen SM, Brajovic S, Hungerford L, St George DM, Dal Pan G. Pinnow E, et al. Among authors: brajovic s. Clin Pharmacol Ther. 2018 Aug;104(2):390-400. doi: 10.1002/cpt.944. Epub 2017 Dec 20. Clin Pharmacol Ther. 2018. PMID: 29266187

6

Postmarketing Safety-Related Regulatory Actions for New Therapeutic Biologics Approved in the United States 2002-2014: Similarities and Differences With New Molecular Entities.

Bulatao I, Pinnow E, Day B, Cherkaoui S, Kalaria M, Brajovic S, Dal Pan G. Bulatao I, et al. Among authors: brajovic s. Clin Pharmacol Ther. 2020 Dec;108(6):1243-1253. doi: 10.1002/cpt.1948. Epub 2020 Sep 8. Clin Pharmacol Ther. 2020. PMID: 32557564 Free PMC article.

7

The Impact of Variability in Patient Exposure During Premarket Clinical Development on Postmarket Safety Outcomes.

Cherkaoui S, Pinnow E, Bulatao I, Day B, Kalaria M, Brajovic S, Dal Pan G. Cherkaoui S, et al. Among authors: brajovic s. Clin Pharmacol Ther. 2021 Dec;110(6):1512-1525. doi: 10.1002/cpt.2320. Epub 2021 Jul 8. Clin Pharmacol Ther. 2021. PMID: 34057195 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

7 results

Search Page

Filters